A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease
- PMID: 27718013
- DOI: 10.1007/s00702-016-1630-6
A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease
Abstract
Despite the well-known neuropsychiatric side effects of dopaminergic medications, the possible subjective psychotomimetic effects of a single dose of L-DOPA in newly diagnosed, drug-naïve patients with Parkinson's disease (PD) are not known. To investigate this question, we used a visual search task for latent inhibition (LI), the Community Assessment of Psychic Experiences (CAPE) scale, and visual analog scales for psychotomimetic effects (perception, relaxation, and dysphoria) in 28 de novo PD patients before (off) and after (on) the adminstration of L-DOPA and in 25 matched healthy control individuals. Results revealed increased LI in PD-off and decreased LI in PD-on relative to the control subjects. After the administration of L-DOPA, we observed a significant decline in LI in PD. L-DOPA also enhanced perceptual experiences (changes in subjective feelings in thinking, time perception, and mental "highness"). Greater reduction in LI was associated with enhanced perceptual experiences. These results suggest that a single dose of L-DOPA has a significant psychotomimetic effect, which is associated with decreased LI, a behavioral marker of psychosis-like experiences.
Keywords: L-DOPA; Latent inhibition; Parkinson’s disease; Psychosis; Psychotomimetic effects.
Similar articles
-
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29. Mov Disord. 2013. PMID: 23630119 Clinical Trial.
-
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.J Neurol Sci. 2007 Jan 31;252(2):130-4. doi: 10.1016/j.jns.2006.10.018. Epub 2006 Dec 28. J Neurol Sci. 2007. PMID: 17196621
-
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20. Exp Neurol. 2015. PMID: 26001615
-
Levodopa: effect on cell death and the natural history of Parkinson's disease.Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11. Mov Disord. 2015. PMID: 25502620 Review.
-
Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.Adv Neurol. 1996;69:545-50. Adv Neurol. 1996. PMID: 8615179 Review. No abstract available.
Cited by
-
NrCAM-deficient mice exposed to chronic stress exhibit disrupted latent inhibition, a hallmark of schizophrenia.Front Behav Neurosci. 2024 Mar 27;18:1373556. doi: 10.3389/fnbeh.2024.1373556. eCollection 2024. Front Behav Neurosci. 2024. PMID: 38601326 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical